Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities.

Permuth JB, Clark Daly A, Jeong D, Choi JW, Cameron ME, Chen DT, Teer JK, Barnett TE, Li J, Powers BD, Kumar NB, George TJ, Ali KN, Huynh T, Vyas S, Gwede CK, Simmons VN, Hodul PJ, Carballido EM, Judge AR, Fleming JB, Merchant N, Trevino JG.

Cancer Med. 2019 Jun;8(6):3314-3324. doi: 10.1002/cam4.2180. Epub 2019 May 9.

2.

Green tea extract for prevention of prostate cancer progression in patients on active surveillance.

Kumar NB, Dickinson SI, Schell MJ, Manley BJ, Poch MA, Pow-Sang J.

Oncotarget. 2018 Dec 28;9(102):37798-37806. doi: 10.18632/oncotarget.26519. eCollection 2018 Dec 28. Review.

3.

India-United States Dialogue on Traditional Medicine: Toward Collaborative Research and Generation of an Evidence Base.

White JD, O'Keefe BR, Sharma J, Javed G, Nukala V, Ganguly A, Khan IA, Kumar NB, Mukhtar H, Pauli GF, Walker L, Sivaram S, Rajaraman P, Trimble EL.

J Glob Oncol. 2018 Sep;4:1-10. doi: 10.1200/JGO.17.00099. Epub 2017 Nov 16.

4.

Thyroid function in the etiology of fatigue in breast cancer.

Kumar NB, Fink A, Levis S, Xu P, Tamura R, Krischer J.

Oncotarget. 2018 May 22;9(39):25723-25737. doi: 10.18632/oncotarget.25438. eCollection 2018 May 22.

5.

Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma.

Poff A, Koutnik AP, Egan KM, Sahebjam S, D'Agostino D, Kumar NB.

Semin Cancer Biol. 2019 Jun;56:135-148. doi: 10.1016/j.semcancer.2017.12.011. Epub 2017 Dec 30. Review.

PMID:
29294371
6.

Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer.

Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ.

Oncotarget. 2017 Jun 29;8(58):99093-99103. doi: 10.18632/oncotarget.18858. eCollection 2017 Nov 17.

7.

Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach.

Leone A, Diorio G, Sexton W, Schell M, Alexandrow M, Fahey JW, Kumar NB.

Oncotarget. 2017 May 23;8(21):35412-35424. doi: 10.18632/oncotarget.16015. Review.

8.

Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.

Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ.

Oncotarget. 2016 Oct 25;7(43):70794-70802. doi: 10.18632/oncotarget.12222.

9.

Racial Differences in the Diagnosis and Treatment of Prostate Cancer.

Pietro GD, Chornokur G, Kumar NB, Davis C, Park JY.

Int Neurourol J. 2016 Nov;20(Suppl 2):S112-119. Epub 2016 Nov 22. Review.

10.

Chemoprevention in African American Men With Prostate Cancer.

Kumar NB, Pow-Sang JM, Spiess PE, Park JY, Chornokur G, Leone AR, Phelan CM.

Cancer Control. 2016 Oct;23(4):415-423.

PMID:
27842331
11.

Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study.

Valecha N, Savargaonkar D, Srivastava B, Rao BH, Tripathi SK, Gogtay N, Kochar SK, Kumar NB, Rajadhyaksha GC, Lakhani JD, Solanki BB, Jalali RK, Arora S, Roy A, Saha N, Iyer SS, Sharma P, Anvikar AR.

Malar J. 2016 Jan 27;15:42. doi: 10.1186/s12936-016-1084-1.

12.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

13.

Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer.

Kumar NB, Quinn GP, Alexandrow MG, Gray J, Schell M, Sutton S, Haura EB.

J Clin Trials. 2014 Sep;4(4). pii: 180.

14.

Broad targeting of resistance to apoptosis in cancer.

Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS.

Semin Cancer Biol. 2015 Dec;35 Suppl:S78-S103. doi: 10.1016/j.semcancer.2015.03.001. Epub 2015 Apr 28. Review.

15.

Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.

Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty J, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn G, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ.

Cancer Prev Res (Phila). 2015 Oct;8(10):879-87. doi: 10.1158/1940-6207.CAPR-14-0324. Epub 2015 Apr 14.

16.

Impact of Dietary Factors and Inflammation on Cognition among Older Adults.

Handing EP, Small BJ, Reynolds SL, Kumar NB.

J Prev Alzheimers Dis. 2015;2(4):220-226. doi: 10.14283/jpad.2015.50.

PMID:
29219165
17.

Distribution & diagnostic efficacy of cardiac markers CK-MB & LDH in pericardial fluid for postmortem diagnosis of ischemic heart disease.

Ghormade PS, Kumar NB, Tingne CV, Keoliya AN.

J Forensic Leg Med. 2014 Nov;28:42-6. doi: 10.1016/j.jflm.2014.09.011. Epub 2014 Oct 7.

PMID:
25440147
18.

Quantitative analysis of injury characteristics in victims of interpersonal violence: an emergency department perspective.

Tingne CV, Shrigiriwar MB, Ghormade PS, Kumar NB.

J Forensic Leg Med. 2014 Aug;26:19-23. doi: 10.1016/j.jflm.2014.06.003. Epub 2014 Jun 11.

PMID:
25066168
19.

Variation in HNF1B and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study.

Chornokur G, Amankwah EK, Davis SN, Phelan CM, Park JY, Pow-Sang J, Kumar NB.

Prostate Cancer. 2013;2013:384594. doi: 10.1155/2013/384594. Epub 2013 Dec 9.

20.

Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival.

Kumar NB, Dhurandhar M, Aggarwal B, Anant S, Daniel K, Deng G, Djeu J, Dou J, Hawk E, Jayaram B, Jia L, Joshi R, Kararala M, Karunagaran D, Kucuk O, Kumar L, Malafa M, Samathanam GJ, Sarkar F, Siddiqi M, Singh RP, Srivastava A, White JD.

Cancer Med. 2013 Feb;2(1):108-15.

21.

Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research.

Chornokur G, Kumar NB.

Cancer Causes Control. 2013 Aug;24(8):1465-80. doi: 10.1007/s10552-013-0241-x. Epub 2013 Jun 5. Review.

22.

Complementary therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Deng GE, Rausch SM, Jones LW, Gulati A, Kumar NB, Greenlee H, Pietanza MC, Cassileth BR.

Chest. 2013 May;143(5 Suppl):e420S-e436S. doi: 10.1378/chest.12-2364.

PMID:
23649450
23.

Buffer Therapy for Cancer.

Ribeiro MD, Silva AS, Bailey KM, Kumar NB, Sellers TA, Gatenby RA, Ibrahim-Hashim A, Gillies RJ.

J Nutr Food Sci. 2012 Aug 15;2:6.

24.

Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers.

Kumar NB, Vadaparampil ST, Mahajan N, Lilienfeld HS, Lee JH, Laronga C, Hakam A, Hein JJ, Egan KM, Arun B, Pal T.

Hereditary Genet. 2012 Jun;1(2). pii: 104. No abstract available.

25.

Data management in clinical research: An overview.

Krishnankutty B, Bellary S, Kumar NB, Moodahadu LS.

Indian J Pharmacol. 2012 Mar;44(2):168-72. doi: 10.4103/0253-7613.93842.

26.

Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer.

Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB.

Eur J Cancer Prev. 2012 Sep;21(5):407-12. doi: 10.1097/CEJ.0b013e32834ef194.

27.

New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer.

Connors SK, Chornokur G, Kumar NB.

Nutr Cancer. 2012;64(1):4-22. doi: 10.1080/01635581.2012.630158. Epub 2011 Nov 18. Review.

28.

Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer.

Chornokur G, Dalton K, Borysova ME, Kumar NB.

Prostate. 2011 Jun 15;71(9):985-97. doi: 10.1002/pros.21314. Epub 2010 Dec 28. Review.

29.

Management of treatment-related symptoms in patients with breast cancer.

Brem S, Kumar NB.

Clin J Oncol Nurs. 2011 Feb;15(1):63-71. doi: 10.1188/11.CJON.63-71. Review.

PMID:
21278042
30.

Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment.

Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Balducci L, Dalton K, Bepler G.

Curr Treat Options Oncol. 2010 Dec;11(3-4):107-17. doi: 10.1007/s11864-010-0127-z. Review.

31.

Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy.

Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Besterman-Dahan K, Krischer JP.

J Soc Integr Oncol. 2010 Winter;8(1):3-13.

32.

Integrated clinical care pathway for managing necrotising soft tissue infections.

Shah AK, Kumar NB, Gambhir RP, Chaudhry R.

Indian J Surg. 2009 Oct;71(5):254-7. doi: 10.1007/s12262-009-0076-6. Epub 2009 Oct 17.

33.

Comparing dietary and other lifestyle factors among immigrant Nigerian men living in the US and indigenous men from Nigeria: potential implications for prostate cancer risk reduction.

Kumar NB, Yu D, Akinremi TO, Odedina FT.

J Immigr Minor Health. 2009 Oct;11(5):391-9. doi: 10.1007/s10903-009-9231-1. Epub 2009 Feb 19.

PMID:
19225888
34.

Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy.

Kumar NB, Besterman-Dahan K, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Krischer JP.

Clin Med Urol. 2008 Apr 16;1:1-14.

35.

Lycopene in the prevention of prostate cancer.

Dahan K, Fennal M, Kumar NB.

J Soc Integr Oncol. 2008 Winter;6(1):29-36. Review.

PMID:
18302908
36.

Safety of purified isoflavones in men with clinically localized prostate cancer.

Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J.

Nutr Cancer. 2007;59(2):169-75.

37.

A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer.

Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J.

Nutr Cancer. 2007;59(2):163-8.

38.
39.
40.
41.

The specific role of isoflavones in reducing prostate cancer risk.

Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J.

Prostate. 2004 May 1;59(2):141-7.

PMID:
15042614
42.

A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells.

Kazi A, Urbizu DA, Kuhn DJ, Acebo AL, Jackson ER, Greenfelder GP, Kumar NB, Dou QP.

Int J Mol Med. 2003 Dec;12(6):879-87.

PMID:
14612961
43.

Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.

Kazi A, Daniel KG, Smith DM, Kumar NB, Dou QP.

Biochem Pharmacol. 2003 Sep 15;66(6):965-76.

PMID:
12963483
44.

Use of complementary/integrative nutritional therapies during cancer treatment: implications in clinical practice.

Kumar NB, Hopkins K, Allen K, Riccardi D, Besterman-Dahan K, Moyers S.

Cancer Control. 2002 May-Jun;9(3):236-43.

PMID:
12060821
45.

The specific role of isoflavones on estrogen metabolism in premenopausal women.

Kumar NB, Cantor A, Allen K, Riccardi D, Cox CE.

Cancer. 2002 Feb 15;94(4):1166-74.

46.
48.

Nutrients in the Chemoprevention of Prostate Cancer: Current and Future Prospects.

Kumar NB, Besterman-Dahan K.

Cancer Control. 1999 Nov;6(6):580-586.

PMID:
10756389
49.

Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact?

Kumar NB, Allen K, Cantor A, Cox CE, Greenberg H, Shah S, Lyman GH.

Breast Cancer Res Treat. 1997 Jun;44(2):135-43.

PMID:
9232272
50.

Timing of weight gain and breast cancer risk.

Kumar NB, Lyman GH, Allen K, Cox CE, Schapira DV.

Cancer. 1995 Jul 15;76(2):243-9.

PMID:
8625099

Supplemental Content

Loading ...
Support Center